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This paper examined the eﬀects of the combined product, Citrus e fructibus/Cydonia e fructibus (Citrus/Cydonia; Citrus and
Cydonia: each 0.01 g/mL), and separate products of Citrus (0.01 g/mL) and Cydonia (0.01 g/mL) on the immunological pathways
involved in seasonal allergic rhinitis (SAR). Peripheral blood mononuclear cells (PBMCs) from five healthy and five grass pollen-
allergic donors were isolated and analyzed in vitro after polyclonal and allergen-specific stimulation of T cells in the presence of
the three extracts. The analyses demonstrated acceptable cell survival with no signs of toxicity. Citrus mainly had a selective eﬀect
on reducing allergen-specific chronic inflammatory (TNF-α; Citrus compared to Cydonia and Citrus/Cydonia: −87.4 (P < 0.001)
and−68.0 (P < 0.05), resp.) and Th2 pathway activity (IL-5; Citrus compared to Cydonia:−217.8 (P < 0.01); while, both Cydonia
and Citrus/Cydonia mainly aﬀected the induction of the allergen-specific Th1 pathway (IFN-γ; Cydonia and Citrus/Cydonia
compared to Citrus: 3.8 (P < 0.01) and 3.0 (P < 0.01), resp.). Citrus and Cydonia demonstrated diﬀerent working mechanisms
in the treatment of SAR and the combination product did not demonstrate larger eﬀects than the separate preparations. Further
eﬀectiveness and eﬃcacy studies comparing the eﬀects of the products on SAR in vivo are indicated.
1. Introduction
Citrus/Cydonia is an anthroposophic medicine, which con-
tains extracts of lemon (Citrus limon (L.) Burm. f.) and
quince (Cydonia oblonga Mill.) [1]. For over eighty years, the
combination of preparations from Citrus and Cydonia has
been prescribed as a subcutaneous injection or nasal spray
for patients who suﬀer from seasonal allergic rhinitis (SAR).
Both in vitro [2, 3] and clinical studies [4–6] have demon-
strated that Citrus/Cydonia might be eﬀective in treating
SAR. Previous immunological analyses demonstrated it has
an eﬀect on the induction of regulatory (IL-10 producing)
T-cell subsets and on the suppression of the Th2 pathway
cytokines, IL-4 and IL-5 [2], in vitro. Another in vitro study
demonstrated that Citrus/Cydonia significantly reduced
the histamine production and the inflammatory mediator
release from mast cells in a dose-dependent manner [3].
Although positive immunomodulating activity has been
reported for the combination product, Citrus/Cydonia, the
extent that each of the two active substances, Citrus and
Cydonia, contribute to the observed eﬀects is not known.
In this in vitro study, we compared the eﬀects of the
combination product, Citrus/Cydonia, and the separate pro-
ducts, Citrus and Cydonia, on SAR-related immunological
components. The primary hypothesis of the present study,
based on traditional use in clinical practice, was that the
combination preparation Citrus/Cydonia would demon-
strate larger SAR-related treatment eﬀects in vitro than the
single preparations of Citrus and Cydonia. The secondary
hypothesis was that treatment with Citrus, Cydonia, and
Citrus/Cydonia would demonstrate larger treatment eﬀects
(as expected in SAR patients) in vitro, in the healthy
group compared to the SAR group. This hypothesis was
based on the assumption that the three products support
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the SAR-related self-healing capacity of the organism and
that this capacity is already stronger in healthy persons than
in SAR patients before treatment.
2. Materials and Methods
This study was conducted according to the study protocol
previously accepted by the medical ethical committee. No
violations or deviations to the study protocol were noticed.
2.1. Investigational Products. The three preparations were
obtained from WALA Heilmittel GmbH (Bad Boll/Eckwa¨ld-
en, Germany). Citrus/Cydonia (Citrus e fructibus/Cydonia e
fructibus, batch number 008 704C) is a solution for sub-
cutaneous injection. One ampoule of 1mL contains: 0.1 g
Citrus medica ssp. limonum e fructibus ferm 33c Dil.
D1 HAB, prescription 33c and 0.1 g Cydonia oblonga e
fructibus ferm 33b Dil. D1 HAB, prescription 33b. Excip-
ients were sodium chloride, sodium hydrogen carbonate
and water for injection. Citrus (Citrus e fructibus, batch
no 008 702C) is a solution for subcutaneous injection.
One ampoule of 1mL contains: 1 g of Citrus medica ssp.
limonum e fructibus ferm 33c Dil. D2 HAB, prescription
33c in a sodium chloride, sodium hydrogen carbonate
solution for injection. Cydonia (Cydonia e fructibus, batch
number 008 703C) is a solution for subcutaneous injection.
One ampoule of 1mL contains 1 g of Cydonia oblonga e
fructibus ferm 33b Dil. D2 HAB, prescription 33b in a
sodium chloride, sodium hydrogen carbonate solution for
injection.
2.2. Blood Donors and Preparation of Blood Samples. Blood
was collected from two groups of participants: SAR patients
and healthy persons. The experiments performed were ap-
proved by the local medical ethical committee, and informed
consent was obtained before sample collection.
Eligible participants from the SAR group were all adults
of both sexes, aged 18 to 40, who gave written informed
consent; suﬀered from SAR for at least two years; had a
RAST score ≥2 for both grass pollen and birch pollen;
suﬀered from the following nasal symptoms: sneezing, itchy
nose, nasal obstruction, and watery nasal discharge; with a
severity score ≥2 for at least three of the four symptoms
(ranging from 0 = not present to 3 = severe) and the
necessity to use antihistamines and/or corticosteroids for
the treatment of symptoms for at least the last two years.
Exclusion criteria were chronic inflammatory autoimmune
diseases such as type I diabetes mellitus, rheumatoid
arthritis, multiple sclerosis, psoriasis, or Crohn’s disease;
being allergic (hypersensitive) to one of the constituents of
Citrus e fructibus/Cydonia e fructibus; asthma; use of other
preparations containing Citrus and/or Cydonia extracts
within the last two weeks prior to enrolment into the study;
use of cromoglycates in the last month before study onset;
concomitant pharmacological treatment indicated for sea-
sonal allergic rhinitis such as antihistamines, corticosteroids,
or other preparations in the last two weeks before study
onset; antiallergy immunotherapy in the previous two years;
participation in a further clinical trial at the same time or
within the previous 4 weeks prior to enrolment into this
study; pregnancy or lactation; severe internal or systemic
disease (e.g., cardiac, hepatic, renal diseases); a known
history of drug, alcohol, and/or medication dependence or
addiction.
Eligible participants from the healthy group were men
and women; aged 18 to 40 who gave written informed
consent; had an RAST score for SAR-related pollen = 0; did
not have the following nasal symptoms during the pollen
season: sneezing, itching nose, nasal obstruction, and watery
nasal discharge; no history of SAR symptoms for at least two
years. Exclusion criteria: chronic inflammatory autoimmune
disease such as type I diabetes mellitus, rheumatoid arthritis,
multiple sclerosis, psoriasis, or Crohn’s disease; allergic
(hypersensitive) to one of the constituents of Citrus e
fructibus/Cydonia e fructibus; asthma; participation in a
further clinical trial at the same time or within the previous
4 weeks prior to enrolment into this study; pregnancy or
lactation; severe internal or systemic disease (e.g., cardiac,
hepatic, renal diseases); drug, alcohol, and/or medication
dependence or addiction.
All eligible participants were recruited from a single
center, the Louis Bolk Institute (Driebergen, NL). The
first participant was included on June 24, 2010, and the
last participant completed the study on August 3, 2010.
Blood samples were taken on July 22, 2010 (2 participants),
July 30, 2010 (5 participants), and August 3, 2010 (3
participants). From each person in the SAR group and
healthy group, 3 × 8mL of blood was collected in sodium
heparinate-coated vacutainers (BD Biosciences, San Diego,
CA, USA). The blood was subsequently diluted 1 : 1 with
Iscove’s Modified Dulbecco’s Media (IMDM) containing
GlutaMAX (IMDM; Gibco-BRL, Paisley, Scotland) before
density gradient centrifugation using Ficoll-Paque PLUS
(Amersham Biosciences, Uppsala, Sweden). The PBMC layer
was washed twice with IMDM and the cell viability and cell
concentration were determined by Trypan blue exclusion.
2.3. Culture Conditions and Stimulations. PBMCs were cul-
tured in Yssel’s medium at 37◦C in a humidified atmosphere
with 5%CO2 at a density of 1×106 viable cells/mL. Immuno-
logical phenotyping of freshly isolated PBMCwas performed
on an FACS Canto II (BD Pharmingen, San Diego, USA),
using monoclonal antibodies and the procedure from BD
Pharmingen (San Diego, USA). Cells were plated out in
48 well plates at a concentration of 1 × 106 cells/mL and
cultured at 37◦C. After five hours, in which the cells adapted
to the culture conditions, various stimuli or a matching
volume of medium were added. Cultures were stimulated
polyclonally with 150 ng/mL anti-CD3 plus 100 ng/mL anti-
CD28 monoclonal antibodies (BD Pharmingen, San Diego,
CA, USA) or cultured in medium only [7]. In addition,
we performed allergen-specific stimulation of 106 cells/mL
in 1mL cultures with applied pollen extract (Phl p 1 from
Timothy grass, Phleum pretense; Biomay Vienna, Austria;
10 μg/mL in medium). Supernatants of the stimulated
cultures were harvested after 1, 4, and 7 days of culture and
stored at −80◦C for later cytokine analysis.
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2.4. Stimulation with Citrus/Cydonia, the Single Products of
Citrus and Cydonia, Relative to Medium Control. Three ex-
perimental conditions and one control condition were eval-
uated. Experimental conditions: (a) Citrus, 0.01 g/mL; (b)
Cydonia, 0.01 g/mL; (c) Citrus/Cydonia, 0.02 g/mL (Citrus
and Cydonia: each 0.01 g/mL). The (negative) control con-
dition and dilution medium was Yssel’s medium. Samples
of culture supernatants were taken after 24 hrs to elucidate
monocyte reactivity, after four days to evaluate the eﬀects
of medium and polyclonal stimulation, and after seven days
to evaluate the eﬀects of the three extracts, Citrus, Cydonia,
and Citrus/Cydonia, relative to a medium control for grass
pollen-specific stimulation. Cytokine concentrations were
measured in culture supernatants using labeled antibody
preparations and flow cytometry measurements.
2.5. Cell Viability. Early apoptosis and late apoptosis/necro-
sis was assessed on freshly prepared and 7-day cultured cells
using double staining with APC-Annexin V and propidium
iodide (PI) [8]. On day 0 half a million cells from the isolated
PBMCs of the individuals were washed and subsequently
incubated with 2 μL Annexin V-APC (BD Biosciences, San
Diego, CA, USA) in 200 μL Annexin V buﬀer according to the
manufacturer’s protocol. After a 15min incubation period,
the cells were spun down (400 g for 10min) and resuspended
in 200 μL Annexin V buﬀer and 2 μL PI (1mg/mL; Sigma,
St. Louis, Mo, USA). The cells were then analyzed on a
flow cytometer (FACS array, BD Biosciences, San Diego, CA,
USA) as detailed in Sections 2.6 and 2.7.
2.6. Immunological Phenotype. On day 0 the immunological
phenotype of PBMC subsets was determined by staining
the surface antigens with the following two monoclonal
antibody (α) mixtures: (1) α-hCD3 (PE-Cy7), α-hCD4 (PE),
α-hCD8 (APC), and α-hCD25 (APC-Cy7); (2) α-hCD3 (PE-
Cy7), α-hCD14 (APC), α-hCD16 (PE), α-hCD19 (APC-
Cy7), and α-hCD56 (PE). All antibodies were purchased
at BD Biosciences (San Diego, CA, USA). For each well,
5 × 105 cells were spun down in a 96 well U-bottom plate.
The cells were incubated with staining buﬀer (1% FCS and
0.1M NaN3 in PBS) containing the surface markers or the
matching isotype controls for 30min on ice in the dark. The
cells were washed once with PBS and resuspended in PBS for
flow cytometry. The four-color flow cytometric acquisition
was performed on an FACS array, using the BD FACS-array
software. An electronic gate was set to exclude debris and at
least 10,000 events/samples were acquired. The percentage of
positive cells was corrected for the isotype control.
2.7. Proliferation Capacity. On days 4 and 7 the proliferation
capacity of the PBMCs was studied by intracellular expres-
sion of the nuclear Ki-67 antigen (Ki-67; BD Pharmingen,
San Diego, CA, USA). The Ki-67 antigen is absent in the
nuclei of resting cells, but present in all other phases of
the cell division cycle as well as in the mitosis phase [8,
9]. In each well, 5 × 105 PBMCs were incubated with
100 μL Cytofix/Cytoperm (BD Pharmingen, San Diego, CA,
USA) for 15 to 20min on ice to fix and permeabilize the
cells. Cells were washed twice with perm/wash buﬀer (BD
Pharmingen, San Diego, CA, USA) and incubated with anti-
Ki-67 PE antibody or the matched isotype control, diluted in
perm/wash buﬀer, for 30min on ice in the dark. Hereafter,
the cells were washed with perm/wash buﬀer, resuspended
in PBS, and measured on the flow cytometer. Values are
expressed as cells positive for the Ki-67 mAb, corrected for
the isotype control.
2.8. Cytokines. On days 1, 4, and 7 PBMC culture super-
natants were analyzed for their IL-1β, IL-12, IFN-γ, TNF-
α, IL-5, IL-10, and IL-13 contents. The cytokine production
was measured with Cytometric Bead Assay Flex Sets (BD
Pharmingen, San Diego, CA, USA). All buﬀers used in this
protocol were obtained from the BD CBA Soluble Protein
Master Buﬀer Kit (BD Pharmingen, San Diego, CA, USA).
Supernatants were collected, stored at −20◦C, and tested
within 2 weeks. The procedure was performed according to
the manufacturer’s protocol. The samples were measured on
the FACS array, using the FCAP software. The sensitivity
limits for quantitative determinations, according to the
manufacturer, were 1.1 pg/mL for IL-1β, 0.3 pg/mL for IFN-
γ, 0.5 pg/mL for IL-5, 2.3 pg/mL for IL-10, 2.2 pg/mL for IL-
12, 0.6 pg/mL for IL-13, and 0.7 pg/mL for TNF-α.
2.9. Definition of Positive Eﬀects. A nonallergic, healthy state
is hypothesized to represent a balanced state within the
immune system with a relatively high level of IL-10 (demon-
strating suﬃcient immunoregulation) and a balance between
the Th1 pathway (e.g., IFN-γ) and the Th2 pathway (e.g.,
IL-5 and IL-13). SAR is associated with relatively low
levels of IL-10, a chronic inflammatory activity (e.g., TNF-
α), an overproduction of Th2 pathway cytokines, and an
imbalance between the Th1 and Th2 pathways [9, 10].
The following changes in cytokine production levels were
therefore regarded as positive immunological SAR treatment
eﬀects [9–14] (Figure 1).
(1) The induction of (regulatory) T cells (Treg): increase
of (grass pollen stimulated minus medium stim-
ulated) IL-10 on day 7, often accompanied by
monocyte-derived IL-10 on day 1.
(2) The induction of Th1 activity: increase of (grass
pollen stimulated minus medium stimulated) IFN-
γ on day 7, often accompanied by monocyte-derived
IFN-γ on day 1.
(3) The reduction of Th2 activity: reduction of (grass
pollen stimulated minus medium stimulated) IL-5
and IL-13 on day 7, often accompanied bymonocyte-
derived IL-1β on day 1, which is essential for the
outgrowth of Th2 cells.
(4) The reduction of chronic inflammatory activity: re-
duction of (grass pollen stimulated minus medium
stimulated) monocyte-derived TNF-α on day 1.
(5) The restoration of the Th1/Th2 balance: an increase
in (grass pollen stimulated minus medium stimu-
lated) IFN-γ/IL-5 and IFN-γ/IL-13 ratios on day 7.
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Figure 1: Seasonal allergic rhinitis related immunological subsystems, pathways, and cytokines.
(6) The restoration of the Treg/Th2 balance: an increase
in the (grass pollen stimulated minus medium stim-
ulated) IL-10/TNF-α ratio on day 1; the increase of
(grass pollen stimulated minus medium stimulated)
IL-10/IL-5 and IL-10/IL-13 ratios on day 7.
2.10. Statistics. Pearson chi-square tests were performed on
all relevant donor characteristics. For the PBMC subsets, we
calculated all immunological outcome parameters (day 1:
IL-1β, IL-10, IL-12, TNF-α, and IFN-γ; day 7: IL-5, IL-13,
IL-10, and IFN-γ), the relevant ratios (day 1: IL10/TNF-α
and IFN-γ/TNF-α; day 7: IL10/IL-5, IL-10/IL-13, IFN-γ/IL-
5, and IFN-γ/IL-13), the mean scores, and 95% confidence
intervals of cytokine production levels after grass pollen
stimulation by subtracting the medium stimulation values.
Subsequently, ANOVA (with Tamhane correction in case
of unequal distribution) and unpaired t-tests were used
to determine statistically significant diﬀerences between (1)
the means of the three SAR groups that were stimulated
in the presence of the three experimental extracts, (2) the
means of the three healthy groups that were stimulated in
the presence of the three experimental extracts, and (3)
the means of the SAR groups and the healthy groups that
were stimulated in the presence of the three experimental
extracts. GLM Repeated Measures tests were performed
to determine statistically significant diﬀerences between
the means of the three total groups (total group = SAR
group and healthy group) that were stimulated in the
presence of the three experimental extracts. All statistical
analyses were performed with SPSS 18.0 (SPSS Inc., Chicago,
USA).
2.11. Blinding. All researchers were blinded to the identity
of the products, which were numbered A, B, and C by the
manufacturer. Unblinding took place after all statistics had
been performed.
3. Results
3.1. Blood Donors. The SAR group and the healthy group
demonstrated no statistically significant diﬀerences with
regard to sex (both groups: 3 women and 2 men); ethnicity
(both groups: all Caucasian); age (means and standard
deviations): 35.2 (10.5) and 43.4 (10.9) years, respectively;
height (means and standard deviations): 1.79 (0.1) and
1.77 (0.1) meters, respectively; weight (means and standard
deviations): 75 (12.6) and 74 (9.2) kg, respectively; systolic
blood pressure (means and standard deviations): 113 (13.2)
and 117 (12.0)Hg, respectively; diastolic blood pressure
(means and standard deviations): 71 (7.5) and 78 (5.7)Hg,
respectively; and heart rate (means and standard deviations):
65 (3.8) and 65 (8.7), respectively. RAST scores (means,
standard deviations and ranges) for grass pollen and birch
pollen respectively were 3.6 (1.5, range: 2–6) and 3.6 (0.9,
range: 3–5) for the SAR group, and 0 and 0 for the healthy
group (Table 1).
The mean percentages of the PBMC subsets for the SAR
group were 58.8% CD3+ T cells (with 40.4% CD4+ Th
cells and 18.4% CD8+ Tc cells), 6.2% CD19+ B cells, 16%
CD14+ monocytes, and 9.6% CD16/CD56+ NK cells. The
mean percentages of the PBMC subsets for the healthy group
were 60.0% CD3+ T cells (with 39.4% CD4+ Th cells and
20.6% CD8+ Tc cells), 7.0% CD19+ B cells, 15.8% CD14+
monocytes, and 8.8% CD16/CD56+ NK cells. There were no
statistically significant diﬀerences in the mean scores of the
subsets between the SAR group and the healthy group.
3.2. Eﬀects on Viability. Citrus (Figure 2(a)), Cydonia
(Figure 2(b)), and Citrus/Cydonia (Figure 2(c)) had no eﬀect
on in vitro cultured blood mononuclear cell survival and
did not appear to be toxic to the PBMC subpopulations by
Annexin V-PI staining.
3.3. Eﬀects on PBMCs from Allergic Donors. The mean cy-
tokine scores after one-day culture and seven-day culture
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Figure 2: Representative example of a flow cytometric analysis profile of live, necrotic, and apoptotic cells after in vitro culture of human
PBMC stimulated in the presence of either Citrus (a) or Cydonia (b) or their combination (c). Citrus (100 μL/mL), Cydonia (100 μL/mL),
or the combination Citrus/Cydonia (100 μL/mL) were added to 0.5 × 106 PBMC in 1mL cultures which were stimulated with grass pollen
extract (10mg/mL) for 7 days. Staining was performed with Annexin V-APC and PI and measured on a BD flow cytometer.
are presented in Tables 2 and 3, respectively, and Figures
3 and 4, respectively. Citrus demonstrated a larger reduc-
tion of chronic inflammatory activity than Cydonia and
Citrus/Cydonia (TNF-α (day 1): −87.4 (95% CI: −120.3 to
−54.5), P < 0.001) and −68.0 (95% CI: −100.9 to −35.1),
P < 0.05, resp.) and had a larger eﬀect on the restoration
of the allergen-specific Treg/Th2 balance (IL-10/TNF-α (day
1): 0.34 (95% CI: 0.20 to 0.49), P < 0.001 and 0.32 (0.17
to 0.47), P < 0.01, resp.). Citrus was also more powerful
than Cydonia in the reduction of Th2 pathway activity in
both the innate reaction (IL-1β (day 1): −12.4 (95% CI:
−22.3 to −2.5), P < 0.05) and the outgrowth of the allergen-
specific specialized T-cell subsets (IL-5 (day 7): −217.8 (95%
CI: −361.9 to −73.7), P < 0.01). Citrus also demonstrated
larger eﬀects than Citrus/Cydonia on the reduction of the
Th2 pathway activity of the allergen-specific specialized T-
cell subsets (IL-13 (day 7): −447.2 (95% CI: −855.9 to 38.5),
P < 0.05). Both Cydonia and Citrus/Cydonia demonstrated
larger eﬀects than Citrus on the innate induction of Th1
pathway activity (IFN-γ (day 1): 3.8 (95% CI: 1.8 to 5.8),
P < 0.01 and 3.0 (95% CI: 1.0 to 5.0), P < 0.01, respectively.
3.4. Eﬀects on the PBMCs from Healthy Donors. Similar to
the results in the allergic donor group (Table 2), Citrus
demonstrated a larger eﬀect in the healthy donor group than
Cydonia and Citrus/Cydonia on the reduction of chronic
inflammatory activity (TNF-α (day 1):−54.6 (95%CI:−84.2
to −25.0), P < 0.01 and −37.6 (95% CI: −67.2 to −8.0),
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Table 1: Baseline characteristics seasonal allergic rhinitis (SAR) group and healthy group.
Variable SAR group (n = 5) Healthy group (n = 5) P value
Sex: number (percentage)
Male 3 (60%) 3 (60%) n.s.
Female 2 (40%) 2 (40%)
Ethnicity: number (percentage)
Caucasian 5 (100%) 5 (100%) n.s.
Asian 0 (0%) 0 (0%)
Age (year) (sd) 35.2 (10.5) 43.4 (10.9) n.s.
Height (cm) (sd) 179 (10) 177 (10) n.s.
Weight (kg) (sd) 75 (12.6) 74 (9.2) n.s.
Blood pressure at screening (systolic/diastolic) (mmHg) (sd) 113 (13.2)/71 (7.5) 117 (12)/78 (5.7) n.s.
Heart rate at screening (beats per minute) 65 (3.8) 65 (8.7) n.s.
RAST grass pollen 3.6 (1.5) 0
RAST birch pollen 3.6 (0.9) 0
n.s. = not significant.
Table 2: Diﬀerences in mean cytokine scores after one-day PBMC cultures in the SAR group, healthy group, and total group (grass pollen
stimulation minus medium stimulation).
Citrus Cydonia Citrus/Cydonia
Citrus versus
Cydonia
P value
Citrus versus
Citrus/Cydonia
P value
Cydonia versus
Citrus/Cydonia
P value
IL-1β∗
SAR 8.2 (7.0) 20.6 (5.0) 14.6 (8.9) P < 0.05 n.s. n.s.
Healthy 2.4 (2.3) 17.6 (6.7) 18.8 (8.0) P < 0.01 P < 0.01 n.s.
Total group 5.3 (5.8) 19.1 (5.8) 16.7 (8.3) P < 0.001 P < 0.01
IL-10
SAR 64.0 (14.4) 59.2 (10.1) 54.0 (8.2) n.s. n.s. n.s.
Healthy 53.0 (15.2) 65.2 (14.4) 69.6 (3.9) n.s. n.s. n.s.
Total group 58.5 (15.1) 62.2 (12.1) 61.8 (10.2) n.s. n.s. n.s.
TNF-α
SAR 94.8 (9.0) 182.2 (15.2) 162.8 (37.4) P < 0.001 P < 0.05 n.s.
Healthy 105.6 (25.2) 160.2 (13.2) 143.2 (23.9) P < 0.01 P < 0.05 n.s.
Total group 100.2 (18.7) 171.2 (17.7) 153.0 (31.3) P < 0.001 P < 0.001
IFN-γ
SAR 3.0 (1.9) 6.8 (1.1) 6.0 (1.2) P < 0.01 P < 0.01 n.s.
Healthy 3.0 (1.6) 6.0 (1.4) 5.4 (1.1) P < 0.01 P < 0.05 n.s.
Total group 3.0 (1.6) 6.4 (1.3) 5.7 (1.2) P < 0.001 P < 0.001
IL-10/
TNF-α
SAR 0.7 (0.1) 0.3 (0.1) 0.4 (0.1) P < 0.001 P < 0.01 n.s.
Healthy 0.5 (0.2) 0.4 (0.1) 0.5 (0.1) n.s. n.s. n.s.
Total group 0.6 (0.2) 0.4 (0.1) 0.4 (0.1) P < 0.01 P < 0.01
∗
The mean score (SD) in pg/mL is presented for all cytokine measurements; n.s., not significant.
P < 0.05, resp.) but not on the restoration of the Treg/Th2
balance (IL-10/TNF-α—day 1). As in the allergic donor
group, Citrus was also more powerful than Cydonia in the
healthy donor group in reducing Th2 pathway activity in
both the innate reaction (IL-1β (day 1): −15.2 (95% CI:
−23.7 to −6.7), P < 0.01) and the outgrowth of the allergen-
specific specialized T-cell subsets (IL-5 (day 7): −217.8 (95%
CI: −371.4 to −64.2), P < 0.01). Unlike the results in
the allergic donor group, Citrus also demonstrated larger
eﬀects than Citrus/Cydonia on the reduction of Th2 pathway
activity in both the innate reaction (IL-1β (day 1): −16.4
(95% CI: −24.9 to −7.9), P < 0.01) and the outgrowth of
the specialized T-cell subsets (IL-5 (day 7): −353.4 (95% CI:
−507.0 to −199.8), P < 0.001). Finally, Citrus was more
powerful than Citrus/Cydonia in restoring the Th1/Th2
balance (IFN-γ/IL-5 (day 7): 0.75 (95% CI: 0.38 to 1.12),
P < 0.01).
Both Cydonia and Citrus/Cydonia also demonstrated
larger eﬀects than Citrus on the innate induction of the Th1
pathway (IFN-γ (day 1): 3.0 (95% CI: 1.1 to 4.9), P < 0.01
and 2.4 (95% CI: 0.5 to 4.3), P < 0.05, resp.). In addition,
Cydonia was more powerful than Citrus/Cydonia on the
allergen-specific T-cell subset related induction of the Th1
pathway (IFN-γ (day 7): 120.6 (95% CI: 10.8 to 230.4), P <
0.05) and the restoration of the Th1/Th2 balance (IFN-γ/IL-
5 (day 7): 0.38 (95% CI: −0.02 to 0.78), P < 0.05) (Table 3).
3.5. Eﬀects on the Total Group. As in the allergic donor group
and the healthy donor group, Citrus demonstrated a larger
reduction of chronic inflammatory activity than Cydonia
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Table 3: Diﬀerences in mean scores after seven-day PBMC cultures in the SAR group, healthy group, and total group (grass pollen
stimulation minus medium stimulation).
Citrus Cydonia Citrus/Cydonia
P value Citrus
versus Cydonia
P value Citrus
versus
Citrus/Cydonia
P value Cydonia
versus
Citrus/Cydonia
IL-10
SAR 88.4 (28.5) 101.4 (19.5) 115.2 (36.2) n.s. n.s. n.s.
Healthy 76.4 (38.2) 107.4 (16.5) 102.4 (26.1) n.s. n.s. n.s.
Total group 82.4 (32.4) 104.4 (17.3) 108.8 (30.5) n.s. n.s. P < 0.05
IL-5
SAR 509,8 (126.6) 727.6 (95.5) 619.0 (87.7) P < 0.01 n.s. n.s.
Healthy 358.0 (81.3) 575.8 (98.6) 711.4 (144.7) P < 0.01 P < 0.001 n.s.
Total group 433.9 (128.3) 651.7 (121.6) 665.2 (122.9) P < 0.01 P < 0.001 n.s.
IL-13
SAR 1470 (390.3) 1823.0 (185.7) 1917.2 (277.7) n.s. P < 0.05 n.s.
Healthy 1589.2 (300.2) 1864.2 (102.0) 1765.4 (186.6) n.s. n.s. n.s.
Total group 1529.6 (334.2) 1843.6 (142.9) 1841.3 (237.0) n.s. n.s. n.s.
IFN-γ
SAR 666.8 (126.2) 724.0 (105.2) 621.4 (90.8) n.s. n.s. n.s.
Healthy 558.0 (130.1) 692.0 (58.4) 571.4 (57.1) n.s. n.s. P < 0.05
Total group 612.4 (133.7) 708.0 (82.0) 596.4 (76.2) P < 0.05 n.s. P < 0.05
IFN-γ/
IL-5
SAR 1.4 (0.5) 1.0 (0.2) 1.0 (0.2) n.s. n.s. n.s.
Healthy 1.6 (0.4) 1.2 (0.2) 0.8 (0.2) n.s. P < 0.01 P < 0.05
Total group 1.5 (0.4) 1.1 (0.2) 0.9 (0.2) P < 0.01 P < 0.001 n.s.
IFN-γ/
IL-13
SAR 0.5 (0.1) 0.4 (0.1) 0.3 (0.1) n.s. n.s. n.s.
Healthy 0.4 (0.1) 0.4 (0.1) 0.3 (<0.1) n.s. n.s. n.s.
Total group 0.4 (0.1) 0.4 (0.1) 0.3 (0.1) n.s. n.s. n.s.
IL-10/
IL-5
SAR 0.2 (0.1) 0.1 (<0.1) 0.2 (0.1) n.s. n.s. n.s.
Healthy 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) n.s. n.s. n.s.
Total group 0.2 (0.1) 0.2 (<0.1) 0.2 (0.1) n.s. n.s. n.s.
IL-10/
IL-13
SAR 0.1 (<0.1) 0.1 (<0.1) 0.1 (<0.1) n.s. n.s. n.s.
Healthy <0.1 (<0.1) 0.1 (<0.1) 0.1 (<0.1) n.s. n.s. n.s.
Total group 0.1 (<0.1) 0.1 (<0.1) 0.1 (<0.1) n.s. n.s. n.s.
∗
The mean score (SD) in pg/mL is presented for all cytokine measurements; n.s., not significant.
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Figure 3: Summary of diﬀerences in mean scores after one-day
PBMC cultures in the SAR group, healthy group, and total group.
and Citrus/Cydonia (TNF-α (day 1): −71.0 (95% CI: −92.5
to −49.5), P < 0.001 and −52.8 (95% CI: −74.3 to −31.3),
P < 0.001, resp.). As in the SAR group, Citrus demonstrated
larger eﬀects than Cydonia and Citrus/Cydonia in the
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Figure 4: Summary of diﬀerences in mean scores after seven days
PBMC cultures in the SAR group, healthy group, and total group.
restoration of the Treg/Th2 balance (IL-10/TNF-α (day 1):
0.23 (95% CI: 0.11 to 0.35), P < 0.01 and 0.17 (95% CI: 0.05
to 0.29), P < 0.01, resp.). As in the allergic donor and healthy
donor groups, Citrus was also more powerful than Cydonia
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in the reduction of Th2 pathway activity in both the innate
reaction (IL-1β (day 1): −13.8 (95% CI: −20.0 to −7.6),
P < 0.001) and the outgrowth of the allergen-specific T-cell
subsets (IL-5 (day 7): −217.8 (95% CI: −331.8 to −103.8),
P < 0.01). As in the healthy donor group, Citrus was also
more powerful than Citrus/Cydonia in the reduction of Th2
pathway activity in both the innate reaction (IL-1β (day 1):
−11.4 (95% CI:−17.6 to−5.2), P < 0.01) and the outgrowth
of the allergen-specific T-cell subsets (IL-5 (day 7): −231.3
(95% CI: −345.3 to −117.3), P < 0.001).
Both Cydonia and Citrus/Cydonia demonstrated larger
eﬀects than Citrus on the innate induction of the Th1
pathway activity (IFN-γ (day 1): 3.4 (95% CI: 2.1 to 4.7),
P < 0.001 and 2.7 (95% CI: 1.4 to 4.0), P < 0.001, resp.),
which was also found in the allergic donor and healthy
donor groups. In addition, Cydonia was more powerful than
both Citrus (unlike the results of the other groups) and
Citrus/Cydonia (like the results in the healthy donor group)
on the allergen-specific T-cell subset related induction of Th1
pathway activity (IFN-γ (day 7): 95.6 (95% CI: 3.2 to 188.0),
P < 0.05) and 111.6 (95% CI: 19.2 to 204.0), P < 0.05,
resp.). In addition, as in the healthy donor group, both Citrus
and Cydonia were more powerful than Citrus/Cydonia in
the restoration of Th1/Th2 balance (IFN-γ/IL-5 (day 7):
0.37 (95% CI: 0.06 to 0.68), P < 0.01 and 0.56 (95% CI:
0.26 to 0.87), P < 0.001, resp.) Finally, unlike the results
in the allergic donor group and the healthy donor group,
Citrus/Cydonia demonstrated a larger eﬀect on the allergen-
specific T-cell subset related induction of Treg activity (IL-10
(day 7): 26.4 (95% CI: 1.1 to 51.7), P < 0.05) (Table 4).
3.6. Comparison of the Eﬀects on PBMCs from Allergic and
Healthy Donors. Statistically significant diﬀerences between
the allergic donor group and the healthy donor group were
demonstrated on day 1 with regard to: TNF-α in the Cydonia
group (182.2 versus 160.2, resp., P < 0.05) and IL-10 (day
1) in the Citrus/Cydonia group (54.0 versus 69.6, resp., P <
0.05); on day 7 with regard to IL-5 in the Citrus group (509.9
versus 358.0, resp., P < 0.05).
3.7. Comparison of the Results in the Diﬀerent Groups. In
all three groups (allergic donor, healthy donor, and total
group) Citrus consistently demonstrated a selective eﬀect on
the reduction of chronic inflammatory activity compared
to the other two extracts and on the reduction of allergen-
specific Th2 pathway activity (Table 4: IL-1β, TNF-α, and IL-
5). Cydonia and Citrus/Cydonia consistently demonstrated a
selective eﬀect on the induction of the innate Th1 pathway
activity compared to Citrus (Table 4: IFN-γ—day 1) in all
three groups.
In the allergic donor group and the total group, Citrus
demonstrated a larger restoration of Treg/Th2 balance com-
pared to the other two extracts (Table 4: IL-10/TNF-α). In the
healthy donor group and the total group, Citrus induced a
reduction in the activity of an allergen-specific, specialized T-
cell subset related Th2 pathway compared to Citrus/Cydonia
(Table 4: IL-5). Citrus also demonstrated a restoration of
the Th1/Th2 balance compared to Citrus/Cydonia (Table 4:
IFN-γ/IL-5) and Cydonia demonstrated a larger eﬀect on the
induction of the allergen-specific, specialized T-cell subset
related Th1 pathway compared to Citrus/Cydonia (Table 4:
IFN-γ-day 7). All analyses with regard to cell viability
demonstrated acceptable cell survival, with no signs of
toxicity, providing evidence for the safety of the three extracts
(data not shown).
4. Discussion
In this in vitro study we examined the immunological
eﬀects of the combined product, Citrus e fructibus/Cydonia
e fructibus (Citrus/Cydonia), and separate products Citrus
and Cydonia on PBMCs from a group of five healthy and five
grass pollen-allergic donors to study possible diﬀerences in
the working mechanisms and magnitude of the eﬀects. Pre-
vious in vitro studies and clinical studies already repeatedly
demonstrated positive treatment eﬀects of Citrus/Cydonia
on immunological and clinical SAR-related elements [2–6].
The primary hypothesis of the present study was that the
combination product Citrus/Cydonia would demonstrate
larger SAR-related immunological treatment eﬀects in vitro
than each of the single products. The secondary hypothesis
was that the healthy group would demonstrate larger SAR-
related immunological treatment eﬀects in vitro than the
SAR group.
In grass pollen allergies, a state of chronic inflammation
in the upper airways is reminiscent of allergen-induced
activity of the innate immune system, which can be analyzed
by the presence of TNF-α and IL-1β on day 1 in allergen-
induced in vitro PBMC cultures. The allergen-induced out-
growth of various T-cell subsets in vitro is widely considered
to be reminiscent of the presence of selected cytokines after
seven days of culture, including IFN-γ (a signature Th1
cytokine), IL-5 (a signature Th2 cytokine), and IL-10 (a
signature Treg cytokine) [9, 10, 13, 14]. Based on our results,
we conclude that Citrus and Cydonia appear to have diﬀerent
working mechanisms. Citrus has mainly a selective eﬀect
on the reduction of chronic inflammatory activity and the
reduction of allergen-specific Th2 pathway activity while
Cydonia has mainly a selective eﬀect on the induction of
the innate related, allergen-specific Th1 pathway activity.
In theory the combination product Citrus/Cydonia would,
therefore, provide an eﬀective therapy that targets SAR
from diﬀerent and possibly additive or synergistic working
mechanisms. However, the empirical results demonstrated
that Citrus/Cydonia does not provide larger eﬀects than the
separate components, both with regard to the reduction of
the allergen-specific Th2 pathway activity and the induction
of the innate related, allergen-specific Th1 pathway activity in
vitro. Thus, the first hypothesis needs to be rejected. Based on
these results, further eﬀectiveness and (placebo) controlled
eﬃcacy studies are indicated to compare the eﬀects of the
three products on SAR in vivo.
The diﬀerences between the SAR group and the healthy
group (TNF-α in the Cydonia group, IL-10 (day 1) in
the Citrus/Cydonia group, and IL-5 in the Citrus group)
and the comparison of the results of both groups (Table 3)
demonstrates overall larger and more eﬀects in the healthy
group. These results implicate eﬀects on both the innate arm
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Table 4: Summary of eﬀects on days 1 and 7 in the SAR group, healthy group, and total group.
Cytokines
(immunological
SAR-related
subset) on day 1
and day 7
SAR group Healthy group Total group
CI versus
CY
CI versus
CI/CY
CY versus
CI/CY
CI versus
CY
CI versus
CI/CY
CY versus
CI/CY
CI versus
CY
CI versus
CI/CY
CY versus
CI/CY
Day 1
IL-1β (Th2) CI∗ CI∗∗ CI∗∗ CI∗∗∗ CI∗∗
TNF-α (Chr. Inf.) CI∗∗∗ CI∗ CI∗∗ CI∗ CI∗∗∗ CI∗∗∗
IFN-γ (Th1) CY∗∗ CI/CY∗∗ CY∗∗ CI/CY∗ CY∗∗∗ CI/CY∗∗∗
IL-10/TNF-α
(Treg/Chr. Inf)
CI∗∗∗ CI∗∗ CI∗∗ CI∗∗
Day 7
IL-10 (Treg) CI/CY∗
IL-5 (Th2) CI∗∗ CI∗∗ CI∗∗∗ CI∗∗ CI∗∗∗
IL-13 (Th2) CI∗
IFN-γ (Th1) CY∗ CY∗ CY∗
IFN-γ/IL-5
(Th1/Th2)
CI∗∗ CY∗ CI∗∗ CI∗∗∗
∗
: P < 0.05; ∗∗: P < 0.01; ∗∗∗: P < 0.001; CI = Citrus; CY = Cydonia; CI/CY = Citrus/Cydonia, Treg = regulatory T cells; Th2 = SAR-related Th2 pathway;
Th1 = SAR-related Th1 pathway; Chron. Inf. = SAR-related chronic inflammatory activity. Example: CI∗∗ (CI versus CY): Citrus (in relation to Cydonia)
demonstrates an SAR-related treatment eﬀect with a statistically significant diﬀerence < 0.01.
of the immune response (monocyte-derived TNF and IL-
10 production) and the potential Th2 arm of the adaptive
immune response (reflected by the IL-5 eﬀect). The second
hypothesis of this study could therefore be confirmed,
providing empirical underpinning of the assumption that the
products support the SAR-related self-healing capacity of the
organism and that this capacity is already stronger in healthy
persons than in SAR patients before treatment.
The positive eﬀects of Citrus and Cydonia are in line with
fundamental studies on the immunomodulating compounds
of these fruits. The extracts of Citrus [15] and Cydo-
nia [16, 17] contain several immunologically active com-
pounds, including organic acids, polyphenols, flavonoids,
and pectins. For example, flavonoids are mainly present in
Citrus fruits as their glycosyl derivatives [18]. Flavonoids
appear to be able to regulate acute and chronic inflammatory
responses and to suppress production of tumor necrosis
factor-α (TNF-α), by macrophages, microglial cells, and
mast cells stimulated with lipopolysaccharide (LPS) and
others via Toll-like receptors (TLRs), and TNF-α-mediated
acute and chronic inflammatory responses [19–21]. And for
example, the pectins in Cydonia extract generally contain a
galacturonic acid. This immunomodulatory compound may
strengthen innate-immune responses that may be beneficial
in specific conditions, such as attenuation of allergic disease
[22, 23].
The major limitation of this study is that it is an in vitro
study that provides, within the classic evidence hierarchy
framework, only limited evidence on the eﬀectiveness of
the examined extracts in vivo. However, the results are
in line with previous in vitro studies [2, 3] and an in
vitro study within an in vivo randomized controlled trial
[5], demonstrating the positive SAR-related immunological
eﬀects of Citrus/Cydonia.
5. Conclusion
It appears that Citrus and Cydonia have diﬀerent working
mechanisms in the treatment of SAR in vitro. Citrus mainly
inhibits the chronic inflammatory activity and the SAR-
related Th2 pathway activity whereas Cydonia mainly pro-
motes the SAR-related Th1 pathway activity. Theoretically,
the combination of both extracts would provide an optimal
treatment that would target SAR from diﬀerent directions.
However, in this in vitro study, the combination product
Citrus/Cydonia did not demonstrate larger eﬀects than
Citrus and Cydonia separately.
The primary hypothesis of the present study, that the
combination preparation Citrus/Cydonia as a whole would
demonstrate larger SAR-related treatment eﬀects in vitro
than each of the single preparations, was rejected. The
secondary hypothesis, that the healthy group would demon-
strate larger SAR-related treatment eﬀects in vitro than the
SAR group, was confirmed.
Future studies could focus on the comparison of the
eﬀects of the separate extracts and the combination product
in vivo.
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